US 10238698
Biomarkers and combination therapies using oncolytic virus and immunomodulation
granted A61KA61K2039/505A61K31/454
Quick answer
US patent 10238698 (Biomarkers and combination therapies using oncolytic virus and immunomodulation) held by The Board of Regents of the University of Texas System expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The Board of Regents of the University of Texas System
- Grant date
- Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 6
- CPC classes
- A61K, A61K2039/505, A61K31/454, A61K35/761, A61K38/2013